These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 33721729)

  • 21. A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice.
    Ramasamy V; Arora U; Shukla R; Poddar A; Shanmugam RK; White LJ; Mattocks MM; Raut R; Perween A; Tyagi P; de Silva AM; Bhaumik SK; Kaja MK; Villinger F; Ahmed R; Johnston RE; Swaminathan S; Khanna N
    PLoS Negl Trop Dis; 2018 Jan; 12(1):e0006191. PubMed ID: 29309412
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design.
    Urakami A; Ngwe Tun MM; Moi ML; Sakurai A; Ishikawa M; Kuno S; Ueno R; Morita K; Akahata W
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28956764
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The human antibody response to dengue virus infection.
    Wahala WM; Silva AM
    Viruses; 2011 Dec; 3(12):2374-95. PubMed ID: 22355444
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Functional analysis of antibodies against dengue virus type 4 reveals strain-dependent epitope exposure that impacts neutralization and protection.
    Sukupolvi-Petty S; Brien JD; Austin SK; Shrestha B; Swayne S; Kahle K; Doranz BJ; Johnson S; Pierson TC; Fremont DH; Diamond MS
    J Virol; 2013 Aug; 87(16):8826-42. PubMed ID: 23785205
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monomeric IgA Antagonizes IgG-Mediated Enhancement of DENV Infection.
    Wegman AD; Fang H; Rothman AL; Thomas SJ; Endy TP; McCracken MK; Currier JR; Friberg H; Gromowski GD; Waickman AT
    Front Immunol; 2021; 12():777672. PubMed ID: 34899736
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dengue viruses are enhanced by distinct populations of serotype cross-reactive antibodies in human immune sera.
    de Alwis R; Williams KL; Schmid MA; Lai CY; Patel B; Smith SA; Crowe JE; Wang WK; Harris E; de Silva AM
    PLoS Pathog; 2014 Oct; 10(10):e1004386. PubMed ID: 25275316
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Virus-like particle secretion and genotype-dependent immunogenicity of dengue virus serotype 2 DNA vaccine.
    Galula JU; Shen WF; Chuang ST; Chang GJ; Chao DY
    J Virol; 2014 Sep; 88(18):10813-30. PubMed ID: 25008922
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of a humanized antibody with high therapeutic potential against dengue virus type 2.
    Li PC; Liao MY; Cheng PC; Liang JJ; Liu IJ; Chiu CY; Lin YL; Chang GJ; Wu HC
    PLoS Negl Trop Dis; 2012; 6(5):e1636. PubMed ID: 22563515
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A broadly neutralizing germline-like human monoclonal antibody against dengue virus envelope domain III.
    Hu D; Zhu Z; Li S; Deng Y; Wu Y; Zhang N; Puri V; Wang C; Zou P; Lei C; Tian X; Wang Y; Zhao Q; Li W; Prabakaran P; Feng Y; Cardosa J; Qin C; Zhou X; Dimitrov DS; Ying T
    PLoS Pathog; 2019 Jun; 15(6):e1007836. PubMed ID: 31242272
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The development of therapeutic antibodies against dengue virus.
    Fibriansah G; Lok SM
    Antiviral Res; 2016 Apr; 128():7-19. PubMed ID: 26794397
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Functional properties of DENV EDIII‑reactive antibodies in human DENV‑1‑infected sera and rabbit antiserum to EDIII.
    Chen J; Wen K; Li XQ; Yi HS; Ding XX; Huang YF; Pan YX; Hu DM; Di B; Che XY; Fu N
    Mol Med Rep; 2016 Aug; 14(2):1799-808. PubMed ID: 27357403
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plant-produced anti-dengue virus monoclonal antibodies exhibit reduced antibody-dependent enhancement of infection activity.
    Dent M; Hurtado J; Paul AM; Sun H; Lai H; Yang M; Esqueda A; Bai F; Steinkellner H; Chen Q
    J Gen Virol; 2016 Dec; 97(12):3280-3290. PubMed ID: 27902333
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic efficacy of antibodies lacking Fcγ receptor binding against lethal dengue virus infection is due to neutralizing potency and blocking of enhancing antibodies [corrected].
    Williams KL; Sukupolvi-Petty S; Beltramello M; Johnson S; Sallusto F; Lanzavecchia A; Diamond MS; Harris E
    PLoS Pathog; 2013 Feb; 9(2):e1003157. PubMed ID: 23459315
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epitope determinants of a chimpanzee dengue virus type 4 (DENV-4)-neutralizing antibody and protection against DENV-4 challenge in mice and rhesus monkeys by passively transferred humanized antibody.
    Lai CJ; Goncalvez AP; Men R; Wernly C; Donau O; Engle RE; Purcell RH
    J Virol; 2007 Dec; 81(23):12766-74. PubMed ID: 17881450
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of two anti-dengue human monoclonal antibodies prepared from PBMCs of patients with dengue illness in Thailand.
    Li ZY; Yamashita A; Kawashita N; Sasaki T; Pan Y; Ono KI; Ikuta K; Li YG
    Acta Virol; 2016 Jun; 60(2):166-73. PubMed ID: 27265466
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development and characterization of serotype-specific monoclonal antibodies against the dengue virus-4 (DENV-4) non-structural protein (NS1).
    Gelanew T; Hunsperger E
    Virol J; 2018 Feb; 15(1):30. PubMed ID: 29409531
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice.
    Frei JC; Wirchnianski AS; Govero J; Vergnolle O; Dowd KA; Pierson TC; Kielian M; Girvin ME; Diamond MS; Lai JR
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29976679
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Paradoxical role of antibodies in dengue virus infections: considerations for prophylactic vaccine development.
    Acosta EG; Bartenschlager R
    Expert Rev Vaccines; 2016; 15(4):467-82. PubMed ID: 26577689
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dengue Virus Envelope Dimer Epitope Monoclonal Antibodies Isolated from Dengue Patients Are Protective against Zika Virus.
    Swanstrom JA; Plante JA; Plante KS; Young EF; McGowan E; Gallichotte EN; Widman DG; Heise MT; de Silva AM; Baric RS
    mBio; 2016 Jul; 7(4):. PubMed ID: 27435464
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dengue virus antibody database: Systematically linking serotype-specificity with epitope mapping in dengue virus.
    Chaudhury S; Gromowski GD; Ripoll DR; Khavrutskii IV; Desai V; Wallqvist A
    PLoS Negl Trop Dis; 2017 Feb; 11(2):e0005395. PubMed ID: 28222130
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.